Lispro insulin in people with non-alcoholic liver cirrhosis and type 2 diabetes mellitus

Gentile, Sandro; Guarino, Giuseppina; Strollo, Felice; Romano, Marco; Genovese, Stefano; Masarone, Mario; Ceriello, Antonio

doi:10.1016/j.diabres.2015.12.006

Cited by 8 publications

(17 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, the summary of product characteristics for insulin lispro also states that renal and hepatic impairment do not affect the glucodynamic response to insulin lispro [ 31 ]. Studies showed that the PK and PD characteristics of insulin lispro were maintained in patients with T1DM and diabetic nephropathy [ 126 ] and that postprandial glucose levels and hypoglycemia rates were lower with insulin lispro than with RHI in patients with T2DM and compensated nonalcoholic liver disease [ 127 ]. Insulin glargine provided better glycemic control than NPH insulin in patients with T2DM on hemodialysis [ 128 ].…”

Section: Basal-bolus Therapy With Insulin Lispro Plus Insulin Glarginmentioning

confidence: 99%

A Review of Basal-Bolus Therapy Using Insulin Glargine and Insulin Lispro in the Management of Diabetes Mellitus

2018

View full text Add to dashboard Cite

Basal-bolus therapy (BBT) refers to the combination of a long-acting basal insulin with a rapid-acting insulin at mealtimes. Basal insulin glargine 100 U/mL and prandial insulin lispro have been available for many years and there is a substantial evidence base to support the efficacy and safety of these agents when they are used in BBT or basal-plus therapy for patients with type 1 or type 2 diabetes mellitus (T1DM, T2DM). With the growing availability of alternative insulins for use in such regimens, it seems timely to review the data regarding BBT with insulin glargine 100 U/mL and insulin lispro. In patients with T1DM, BBT with insulin glargine plus insulin lispro provides similar or better glycemic control and leads to less nocturnal hypoglycemia compared to BBT using human insulin as the basal and/or prandial component, and generally provides similar glycemic control and rates of severe hypoglycemia to those achieved with insulin lispro administered by continuous subcutaneous insulin infusion (CSII). Studies evaluating BBT with insulin glargine plus insulin lispro in patients with T2DM also demonstrate the efficacy and safety of these insulins. Available data suggest that BBT with insulin glargine and insulin lispro provides similar levels of efficacy and safety in pediatric and adult populations with T1DM and in adult patients and those aged more than 65 years with T2DM. These insulin preparations also appear to be safe and effective for controlling T2DM in people of different ethnicities and in patients with T1DM or T2DM and comorbidities.FundingEli Lilly and Company.

show abstract

Section: Basal-bolus Therapy With Insulin Lispro Plus Insulin Glarginmentioning

confidence: 99%

A Review of Basal-Bolus Therapy Using Insulin Glargine and Insulin Lispro in the Management of Diabetes Mellitus

2018

View full text Add to dashboard Cite

show abstract

“…Careful adjustment of the insulin dose and close monitoring of blood glucose levels may enable the effective and safe use of insulin for treating persons with cirrhosis and T2DM [ 6 ]. However, insulin has some deleterious side effects.…”

Section: Introductionmentioning

confidence: 99%

Is insulin the preferred treatment in persons with type 2 diabetes and liver cirrhosis?

Yen¹,

Wei

Chiu

et al. 2021

BMC Gastroenterol

View full text Add to dashboard Cite

Background Insulin is highly recommended for diabetes management in persons with liver cirrhosis. However, few studies have evaluated its long-term effects in these persons. We conducted this study to compare the risks of mortality, liver-related complications, and cardiovascular events in persons with type 2 diabetes mellitus (T2DM) and compensated liver cirrhosis. Methods From January 1, 2000, to December 31, 2012, we selected 2047 insulin users and 4094 propensity score-matched nonusers from Taiwan’s National Health Insurance Research Database. Cox proportional hazard models were used to assess the risks of outcomes. Results The mean follow-up time was 5.84 years. The death rate during the follow-up period was 5.28 and 4.07 per 100 person-years for insulin users and nonusers, respectively. In insulin users, the hazard ratios and 95% confidence intervals (CIs) of all-cause mortality, hepatocellular carcinoma, decompensated cirrhosis, hepatic failure, major cardiovascular events, and hypoglycemia were 1.31 (1.18–1.45), 1.18 (1.05–1.34), 1.53 (1.35–1.72), 1.26 (1.42–1.86), 1.41 (1.23–1.62), and 3.33 (2.45–4.53), respectively. Conclusions This retrospective cohort study indicated that among persons with T2DM and compensated liver cirrhosis, insulin users were associated with higher risks of death, liver-related complications, cardiovascular events, and hypoglycemia compared with insulin nonusers.

show abstract

“…В настоящее время идет активное изучение изменения фармакокинетики различных инсулинов у пациентов с ПН. Полученные данные позволяют отметить предпочтительность аналогов инсулина человека [17,18]. Согласно действующим клиническим рекомендациям ведущих медицинских организаций США, Европы и России, противопоказаний и ограничений в назначении инсулинотерапии нет.…”

Section: тиазолидиндионы (тзд)unclassified

Diabetes mellitus and chronic liver diseases. Literature review (part 2): treatment features

Калмыкова

Кононенко

Mayorov

et al. 2019

Terapevticheskii arkhiv

View full text Add to dashboard Cite

Diabetes mellitus (DM) and chronic liver disease (CLD) are pathological conditions associated with each other and reaching epidemic proportions. There is a strong pathogenetic relationship of carbohydrate metabolism disorders and a number of CLD. Common mechanisms that provoke metabolic and autoimmune disorders in the development of various CLD, leading to steatosis, insulin resistance (IR), impaired glucose tolerance and the development of DM are described. Effective glycemic control can have a beneficial effect on the treatment of these patients, and, conversely, there is evidence of a positive effect of CLD therapy on carbohydrate metabolism. This review discusses the correction of carbohydrate metabolism in patients with CLD, the main groups of modern hypoglycemic drugs, mechanisms of their action, the impact on the physiology of the liver, the possibility of using each of these pharmacological groups in patients with impaired liver function. The modern approaches and possibilities of drug effects on the process of fibrogenesis in CLD, the effect of these drugs on carbohydrate metabolism are listed.

show abstract

Lispro insulin in people with non-alcoholic liver cirrhosis and type 2 diabetes mellitus

Cited by 8 publications

References 23 publications

A Review of Basal-Bolus Therapy Using Insulin Glargine and Insulin Lispro in the Management of Diabetes Mellitus

A Review of Basal-Bolus Therapy Using Insulin Glargine and Insulin Lispro in the Management of Diabetes Mellitus

Is insulin the preferred treatment in persons with type 2 diabetes and liver cirrhosis?

Diabetes mellitus and chronic liver diseases. Literature review (part 2): treatment features

Contact Info

Product

Resources

About